Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
26)17-5-6-18-19(14-17)28-12-11-27-18/h1
TRIM24-C34 was used at 10 µM final concentration in various in vitro assays
1007/s12020-015-0590-1
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
486427-17-2
MLN-9708 - CAS# 1239908-20-3 60262 26)17-5-6-18-19(14-17)28-12-11-27-18/h1MLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved